1621924-38-6

Basic information

• Product Name: (2S,4S)-2-tert-butoxycarbonylamino-4-methylpentanedioic acid 1-benzyl ester 5-methyl ester
• Synonyms: (2S,4S)-2-tert-butoxycarbonylamino-4-methylpentanedioic acid 1-benzyl ester 5-methyl ester
• CAS NO: 1621924-38-6
• Molecular Weight: 365.426
• Mol File: 1621924-38-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,4S)-2-tert-butoxycarbonylamino-4-methylpentanedioic acid 1-benzyl ester 5-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4S)-2-tert-butoxycarbonylamino-4-methylpentanedioic acid 1-benzyl ester 5-methyl ester(1621924-38-6)
• EPA Substance Registry System: (2S,4S)-2-tert-butoxycarbonylamino-4-methylpentanedioic acid 1-benzyl ester 5-methyl ester(1621924-38-6)

Safety Data

• Hazardous Substances Data: 1621924-38-6(Hazardous Substances Data)

Upstream product

• 132245-78-4 (S)-2-tert-butoxycarbonylaminopentanedioic acid 1-benzyl ester 5-methyl ester 
• 74-88-4 methyl iodide 
• 30924-93-7 Boc-Glu-OBn 

Downstream Products

• 1621924-52-4 (2S,4S)-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methyl-4-[(5-phenylpyridine-2-carbonyl)amino]butyric acid 
• 1621924-15-9 (2S,4S)-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methyl-4-[(5-phenylpyridine-3-carbonyl)amino]butyric acid methyl ester 
• 1621924-26-2 (2S,4S)-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methyl-4-[(4-phenylpiperidine-1-carbonyl)amino]butyric acid methyl ester 
• 1621924-49-9 (2S,4S)-4-tert-butoxycarbonylamino-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methylbutyric acid methyl ester 
• 1621924-51-3 (2S,4S)-4-amino-4-[2-(4-fluorophenyl)-1,1-dimethylethylcarbamoyl]-2-methylbutyric acid methyl ester trifluoroacetate 

Relevant articles and documents

SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ADAMTS5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.